dotMD.com
✓ Translated by DotMD AI Clinical Council Source: The American journal of psychiatry • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #16816220
Plain-English Research Story • 8th-Grade Reading Level

New Insights on Mirtazapine and nortriptyline following two consecutive failed medication: What a 235-Participant Study Found

Switching to a third antidepressant single-drug treatment regimen after two consecutive unsuccessful antidepressant trials resulted in low full symptom relief rates (<20%) among patients with depression.

Original Paper Title: “A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report” (The American journal of psychiatry, 2006-07-15)

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 235
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: Switching to a third antidepressant single-drug treatment regimen after two consecutive unsuccessful antidepressant trials resulted in low full symptom relief rates (<20%) among patients with depression.
  • Who Was Studied: Randomized Controlled Trial published in The American journal of psychiatry following 235 real-world participants.
  • Strength of the Evidence: Earned a 82/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Few controlled studies have addressed the issue of which antidepressant medications should be recommended for outpatients who have not responded to multiple treatment trials. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in The American journal of psychiatry conducted a randomized controlled trial evaluating 235 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

Switching to a third antidepressant single-drug treatment regimen after two consecutive unsuccessful antidepressant trials resulted in low full symptom relief rates (<20%) among patients with depression. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in The American journal of psychiatry (2006-07-15) • Study Design: Randomized Controlled Trial • Participants: N = 235 • Biostatistical Rigor Score: 82/100. Primary Takeaway: Switching to a third antidepressant single-drug treatment regimen after two consecutive unsuccessful antidepressant trials resulted in low full symptom relief rates (<20%) among patients with depression.

Study Limitations & Caveats Before You Act

While this randomized controlled trial scored 82/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report”
Published in The American journal of psychiatry (2006-07-15) • PMID/ID: 16816220
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 16816220: New Insights on Mirtazapine and nortriptyline following two consecutive failed medication: What a 235-Participant Study Found

3 of 3 Free Questions Remaining